Fully Human BAFF-R Chimeric Antigen Receptor T-Cell (Taihe Chunyu)

全人源 BAFF-R嵌合抗原受体T细胞 (泰禾春雨)

Report date: 2026/05/14 20:00:28

Base Information

Drug NameFully Human BAFF-R Chimeric Antigen Receptor T-Cell (Taihe Chunyu)
Drug Alias NameBAFF-R CAR-T (Taihe Chunyu)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell activating factor receptor modulators
TargetsB-cell activating factor receptor
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell, Marginal Zone +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHebei Tahoe Chunyu Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHebei Tahoe Chunyu Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsWaldenstrom MacroglobulinemiaLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell, Marginal Zone +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A